Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Refractory Follicular Helper T-Cell Lymphoma, Follicular-Type”

9 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 9 of 9 results

Large-scale testing (Phase 3)WithdrawnNCT04021082
What this trial is testing

CELTIC-1: A Phase 2B Study of Cerdulatinib in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL)

Who this might be right for
Peripheral T-Cell Lymphoma (PTCL NOS)Nodal Lymphomas of T Follicular Helper (TFH)Follicular T-cell Lymphoma (FTCL)+6 more
Portola Pharmaceuticals
Early research (Phase 1)Active Not RecruitingNCT02520791
What this trial is testing

Anti-ICOS Monoclonal Antibody MEDI-570 in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Follicular Variant or Angioimmunoblastic T-cell Lymphoma

Who this might be right for
Advanced Primary Cutaneous T-Cell Non-Hodgkin LymphomaRecurrent Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-TypeRecurrent Grade 1 Follicular Lymphoma+16 more
National Cancer Institute (NCI)
Testing effectiveness (Phase 2)Ended earlyNCT04251065
What this trial is testing

Daratumumab Plus Gemcitabine, Dexamethasone, Cisplatin in pt R/R CD38+ PTCL-NOS, AITL and TFH

Who this might be right for
Refractory T-Cell LymphomaRelapsed T-Cell Lymphoma
Fondazione Italiana Linfomi - ETS 8
Testing effectiveness (Phase 2)Study completedNCT02464228
What this trial is testing

Investigation of Tipifarnib in Treatment of Subjects With Peripheral T-Cell Lymphoma (PTCL) That Have Not Responded to Standard Therapy

Who this might be right for
Relapsed or Refractory Peripheral T-Cell Lymphoma
Kura Oncology, Inc. 65
Large-scale testing (Phase 3)Looking for participantsNCT06522737
What this trial is testing

Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype

Who this might be right for
Lymphoma
SecuraBio 124
Testing effectiveness (Phase 2)Temporarily pausedNCT06761677
What this trial is testing

A Phase 1b/2 Study of Intravenous Brincidofovir in Patients With Relapsed or Refractory Lymphoma and Relapsed or Refractory Extranodal Natural Killer/T-cell Lymphoma

Who this might be right for
Relapsed or Refractory Lymphoma Including ENKL
SymBio Pharmaceuticals 43
Testing effectiveness (Phase 2)Active Not RecruitingNCT06035497
What this trial is testing

Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3)

Who this might be right for
Relapsed or Refractory T-cell Lymphomas
Bristol-Myers Squibb 85
Early research (Phase 1)Not Yet RecruitingNCT07691450
What this trial is testing

Belinostat in Combination With Azacitidine or Pralatrexate for the Treatment of Relapse or Refractory T-cell Lymphoma

Who this might be right for
Recurrent Anaplastic Large Cell LymphomaRecurrent Enteropathy-Associated T-Cell LymphomaRecurrent Follicular Helper T-Cell Lymphoma+23 more
City of Hope Medical Center 40
Large-scale testing (Phase 3)Looking for participantsNCT06561048
What this trial is testing

Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma

Who this might be right for
Peripheral T-Cell Lymphoma, Not Otherwise SpecifiedAngioimmunoblastic T-cell LymphomaFollicular T-Cell Lymphoma+4 more
Corvus Pharmaceuticals, Inc. 150
21